glp 1 sanofi ADA 2021: Hanmi's GLP-1 drug, returned by Sanofi, curbs cardiovascular, kidney issues while tackling Type 2 diabetes Latin America Glucagon-like Peptide-1 Agonists
Description
A series of interrelated signals causes GLP-1RAs to have their complicated metabolic effects
GLP-1 RA use is associated with a greater but moderate reduction in HbA 1c and lower risk of DKA when compared with SGLT2i therapy
Diabetes Complications 31 , 218222 (2017)
doi: 10.1172/jci.insight.133429 45 GaileyJ
The effectiveness of Semaglutide GLP-1 in non-diabetics is primarily attributed to its mechanism of action, which involves mimicking the hormone GLP-1 to regulate appetite and calorie intake effectively
